New to Meducation?
Sign up
Already signed up? Log In
view moderators

LungNeoplasms

Category

Preview
0
8

Knowledge About LDCT Lung Cancer Screening Low

A small survey of South Carolina family physicians found reluctance in referring high-risk patients for LDCT screening despite multiple professional organizations' recommendations.  
medscape.com
over 3 years ago
Preview
0
9

Breath Analysis Normalizes After Lung Cancer Resection

The levels of exhaled carbonyl compounds decrease to normal after lung cancer resection, researchers report.  
medscape.com
over 3 years ago
Preview
0
11

Web App Ups Lung Cancer Survival by 7 Months

In a phase 3 randomized clinical trial, cancer care enhanced by a web application improved overall survival by 7 months over standard care.  
medscape.com
over 3 years ago
Preview
0
9

Novel Antibody Shows Efficacy in Small-Cell Lung Cancer

Early data show promising activity in small-cell lung cancer with a new antibody-drug conjugate that targets delta-like protein DLL3.  
medscape.com
over 3 years ago
Preview
0
8

Monday at ASCO: Helping Patients to Help Themselves

Lung cancer patients lived longer when they used a smartphone to report symptoms to a web-based application that triggered alerts to oncologists.  
medscape.com
over 3 years ago
Preview
0
8

FDA OKs First Liquid Biopsy for Lung Cancer Mutation

The blood-based genetic test is a companion diagnostic for erlotinib and for use in patients with non-small cell lung cancer.  
medscape.com
over 3 years ago
Preview
0
8

Antibody-Drug Conjugates, Targeted Therapies Lead Lung Cancer Data

Dr Mark Kris 'whets our appetites' for what's ahead at ASCO 2016 for lung cancer management, including new antibody-drug conjugates and targeted therapies.  
medscape.com
over 3 years ago
Preview
0
7

Lung Cancer Sessions Focus on Immunotherapy, Genomics

From diagnosis using molecular markers to targeted treatment, Dr Mark Kris details which studies from ASCO 2016 he thinks will help clinicians and patients fight lung cancer.  
medscape.com
over 3 years ago
Preview
0
7

Acquired Resistance in Lung Cancer: When to Switch Agents

Rociletinib and osimertinib appear to be on the verge of approval. Dr Mark Kris discusses how their arrival may affect clinical decisions at the time of acquired resistance in lung cancer.  
medscape.com
over 3 years ago
Preview
0
6

Prolyl Isomerase Pin1 Expression in Lung Adenocarcinoma

The findings of this study suggest that inhibition of Pin1 activity could be a novel strategy for lung cancer treatment.  
medscape.com
over 3 years ago
Preview
0
6

Radon in Home Now Linked to Blood Cancers in Women

Radon exposure in the home, already linked to lung cancer, has now been shown to increases the risk for hematologic malignancy in women, although not in men.  
medscape.com
over 3 years ago
Preview
0
11

Using Immunohistochemistry to Predict Anti-PD1/PDL1 Activity

Which patients with lung cancer will respond to anti-PD-1/PD-L1 therapies?  
medscape.com
over 3 years ago
Preview
0
8

New Immunotherapies Bring New Questions in Lung Cancer

Dr Mark Kris assesses the complicated risks and benefits of using nivolumab and pembrolizumab for patients with lung cancers.  
medscape.com
over 3 years ago
Preview
0
7

Next-Gen Sequencing Every Lung Cancer: Lessons From France

A large French study has clearly demonstrated the benefit of completely sequencing every lung cancer, says Dr Mark Kris.  
medscape.com
over 3 years ago
Preview
0
7

Are Clinically Diagnosed Lung Cancer Patients Overtreated?

Clinically diagnosed early-stage lung cancer patients have significantly longer cancer-specific survival than pathologically diagnosed patients, suggesting they are overtreated for benign disease.  
medscape.com
over 3 years ago
Preview
0
6

Lung Cancer Admissions Down, but Hospital Costs Up

Although the number of admissions for lung cancer and in-hospital mortality decreased significantly over the past decade, the cost per hospitalization almost doubled, say US investigators.  
medscape.com
over 3 years ago
Preview
0
7

Lung Cancer Clinicians Urged to Look Beyond RCT Data

Given the difficulties in conducting randomized controlled trials in lung cancer, clinicians should look to observational and registry data to support decision-making, said a leading expert.  
medscape.com
over 3 years ago
Preview
0
6

FDA Panel Denies Accelerated Approval of Lung Cancer Drug

A rival drug was the elephant in the room at the Oncologic Drugs Advisory Committee meeting, where the panel voted against rociletinib.  
medscape.com
over 3 years ago
Preview
0
7

Multidisciplinary Care Takes Center Stage at ELCC 2016

Immunotherapy, oncogene inhibition, and the role of surgery and radiotherapy will be discussed at the European Lung Cancer Conference (ELCC) 2016 in Geneva.  
medscape.com
over 3 years ago
Preview
0
7

A Dose of Reality in Low-Dose CT Lung Cancer Screening

Some controversy remains regarding the adoption of wide-scale LDCT screening for lung cancer.  
medscape.com
over 3 years ago